Navigation Links
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Date:2/6/2008

Data also showed differences in gastrointestinal and lipid effects between

REYATAZ/ritonavir and lopinavir/ritonavir among study population

PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the CASTLE study, in which 300 mg of once-daily REYATAZ(R) (atazanavir sulfate) taken with 100 mg of ritonavir (REYATAZ/r) showed similar antiviral efficacy to twice-daily lopinavir 400 mg and ritonavir 100 mg (lopinavir/r) in previously untreated adult HIV-1 infected patients at 48 weeks, as part of HIV combination therapy. In this study, 78 percent of the 440 patients in the REYATAZ/r arm met the primary endpoint of achieving undetectable viral load (defined as HIV-1 RNA less than 50 copies/mL) at 48 weeks, compared with 76 percent of the 443 patients in the lopinavir/r arm.

CASTLE is the first large-scale, open-label, randomized study designed to demonstrate the non-inferiority of REYATAZ/r to lopinavir/r in previously untreated HIV-1 infected adult patients. Data from the CASTLE study were presented for the first time at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) this week in Boston, Mass.

"The CASTLE study provides important additional data to inform the use of a once-daily regimen including REYATAZ and ritonavir in antiretroviral-naive HIV-infected patients," said Jean-Michel Molina, M.D., Hopital Saint Louis, Paris, France. "When choosing a treatment in previously untreated patients it is important to ensure antiviral activity as well as tolerability to optimize the management of HIV infection over the long term."

The most common grade 2-4 adverse events occurring in greater than or equal to three percent of patients
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
2. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
3. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Inverseon Announces Positive Phase IIa Asthma Study
6. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
7. Study Says Allergy Shots Help Children, Reduce Health Care Costs
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
10. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Trial... -- MONT-SAINT-GUIBERT, Belgium, November 17, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... 2010 In response to an expressed need by ... facilitate the sharing and exchanging of data among PMP ... will be developing an interconnected communications hub for state ... nine months, will be made accessible to the states ...
Cached Medicine Technology:Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 2Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 3Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 4Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 5Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 6Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 7Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 8Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 9Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 10Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 11Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 12NABP Developing System to Link Prescription Monitoring Programs Across States to Facilitate Data Exchange 2
(Date:4/23/2014)... health benefits of probiotics, antioxidants and other nutritional compounds, ... chemical industry is getting in on the action. But ... so the industry is responding with clinical research to ... in Chemical & Engineering News (C&EN), the ... Melody M. Bomgardner, a senior editor at C&EN, writes ...
(Date:4/23/2014)... concerned about an increase in adolescents, marijuana use following ... of relief. According to a new study at Rhode ... from states with and without medical marijuana laws, legalizing ... adolescents. The study is published online in advance of ... , "Any time a state considers legalizing medical ...
(Date:4/23/2014)... the bottom of Alzheimer,s disease has been a ... controversies. In the latest crook in the research ... the interaction between proteins associated with the disease. ... ACS Chemical Neuroscience , could have important implications ... Krzysztof Nieznanski and colleagues explain that for years, ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... The International Communication Association will hold its 64th ... theme of the 2014 conference will explore what ... digital society. , Featuring over 2,300 academic papers ... scholars representing over 40 countries, the ICA conference ... the world. This year,s conference features sessions that ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... content talking to an imaginary friend rather than a real one ... such a pal can have a positive effect on children. ... in London also insists that imaginary friends are not a sign ... his or her age group, but a sign that your child ...
... drugs may give a man's performance in bed a boost, ... or their relationships . ,A survey of ... have poorer esteem, a weaker sense of masculinity and lower ... dysfunction (ED), including half who had tried drug treatment, and ...
... hope revived for women who feel less than that, after ... claim that stem cells found in the ubiquitous tummy fat ... this is so, it would be killing two birds with ... ,Christened Celution, the procedure involves injecting a 'supercharged' fat ...
... Dr. Endress and his colleagues found that the sizes ... buzz-pollinating bees . The male floral structures, anthers, release ... ,Unlike moths and butterflies that are often brilliantly ... flowers and the fruits they produce have brilliant colors ...
... increases a person's risk of colon cancer by 23 percent ... by a team of researchers from the University of Michigan ... Institute of Oncology in Spain, the CHS National Israeli Cancer ... including Stephen Gruber and Gad Rennert. ,As part ...
... treatments using their knowledge about an obesity drug, orlistat (Xenical ... the laboratory . ,The drug binds and interacts ... protein's function and causes cell death. ,The study ... and W. Todd Lowther at Wake Forest University School of ...
Cached Medicine News:Health News:Stem Cells In Belly Fat To Enhance Or Reconstruct Breasts 2Health News:Size and Position of Floral Anther Plays a Vital Role in Pollination 2Health News:Size and Position of Floral Anther Plays a Vital Role in Pollination 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: